Formoterol 12 micrograms inhalation powder, hard capsule Ireland - English - HPRA (Health Products Regulatory Authority)

formoterol 12 micrograms inhalation powder, hard capsule

laboratorios liconsa, s.a. - formoterol fumarate - inhalation powder, hard capsule - 12 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

MARBETA L KIT- betamethasone sodium phosphate, betamethasone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidi United States - English - NLM (National Library of Medicine)

marbeta l kit- betamethasone sodium phosphate, betamethasone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidi

asclemed usa, inc. - betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - betamethasone 3 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.4, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection/bupivacaine hydrochloride and epinephrine injection is contraindicated

MARBETA 25 KIT- betamethasone sodium phosphate and betamethasone acetate, bupivacaine hydrochloride, povidine iodine kit United States - English - NLM (National Library of Medicine)

marbeta 25 kit- betamethasone sodium phosphate and betamethasone acetate, bupivacaine hydrochloride, povidine iodine kit

asclemed usa, inc. - betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - betamethasone 3 mg in 1 ml - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration (2.2)]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration (2.2), contraindications (4), warnings and precautions (5.1, 5.4, 5.5, 5.7, 5.9)] . bupivacaine hydrochloride injection/bupivacaine hydrochloride and epinephrine injection is contraindicated

TOBETA-XL metoprolol succinate 47.5 mg modifed release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 47.5 mg modifed release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; sodium stearylfumarate; triethyl citrate; croscarmellose sodium; purified talc; macrogol 6000; silicified microcrystalline cellulose; silicon dioxide; methacrylic acid copolymer; povidone; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate190 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate190 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 190 mg - tablet, modified release - excipient ingredients: povidone; methacrylic acid copolymer; croscarmellose sodium; ethylcellulose; purified talc; sodium stearylfumarate; microcrystalline cellulose; macrogol 6000; triethyl citrate; silicified microcrystalline cellulose; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 23.75 mg modified release tablet bottle pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 23.75 mg modified release tablet bottle pack

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; sodium stearylfumarate; macrogol 6000; povidone; purified talc; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolo succinatel 47.5 mg modified release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolo succinatel 47.5 mg modified release tablet bottle

pharmacor pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: triethyl citrate; sodium stearylfumarate; povidone; silicified microcrystalline cellulose; croscarmellose sodium; ethylcellulose; microcrystalline cellulose; purified talc; methacrylic acid copolymer; silicon dioxide; macrogol 6000; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 95 mg modified release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 95 mg modified release tablet bottle

pharmacor pty ltd - metoprolol succinate, quantity: 95 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; triethyl citrate; povidone; silicified microcrystalline cellulose; microcrystalline cellulose; silicon dioxide; ethylcellulose; purified talc; macrogol 6000; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 23.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 23.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: purified talc; macrogol 6000; microcrystalline cellulose; povidone; silicon dioxide; triethyl citrate; sodium stearylfumarate; croscarmellose sodium; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 95 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 95 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 95 mg - tablet, modified release - excipient ingredients: silicified microcrystalline cellulose; purified talc; macrogol 6000; methacrylic acid copolymer; microcrystalline cellulose; povidone; croscarmellose sodium; ethylcellulose; silicon dioxide; triethyl citrate; sodium stearylfumarate; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.